Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06360822 · ClinicalTrials.gov registry record · NA

Increasing Equity in Lung Cancer Screening

A NA study of Lung Cancer, sponsored by Indiana University.

Recruiting
Registry status
NA
Development phase
144
Enrollment target
1
Study location

NCT06360822: Recruiting NA study of Lung Cancer, sponsored by Indiana University.

NCT06360822 is a NA study of Lung Cancer that is actively recruiting participants, run by Indiana University. The registered enrollment target is 144 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06360822, a NA study of Lung Cancer, is actively recruiting participants, sponsored by Indiana University.

RECRUITING
Registry status
NA
Development phase
144 participants
Enrollment target
1
Study location

Study Summary

The overall objective of this mixed methods study is to: 1) Refine the Emergency Department Lung Cancer Screening (ED-LCS) intervention using qualitative interviews among key stakeholders; 2) pilot test the ED-LCS intervention evaluating the intervention efficacy, acceptability, and feasibility; and 3) provide an in-depth description of stakeholders' experiences with the ED-LCS intervention for future refinement.

Conditions Studied

Interventions

  • BEHAVIORAL ED-LCS

Study Locations (1)

Indiana

  • Eskenazi Health - Indianapolis

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2023-12-01
Est. Completion 2027-02-01
Phase NA

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT06360822

The ClinicalTrials.gov registry entry for NCT06360822 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which ED-LCS is the first listed.

NCT06360822 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT06360822 about?

NCT06360822 is a clinical study titled "Increasing Equity in Lung Cancer Screening". The overall objective of this mixed methods study is to: 1) Refine the Emergency Department Lung Cancer Screening (ED-LCS) intervention using qualitative interviews among key stakeholders; 2) pilot test the ED-LCS intervention evaluating the intervention efficacy, acceptability, and feasibility; and...

What is the current status of trial NCT06360822?

This trial is currently recruiting. It is a NA study. The enrollment target is 144 participants. The study started on 2023-12-01. Estimated completion is 2027-02-01.

What conditions does trial NCT06360822 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT06360822?

The interventions under investigation include: ED-LCS (BEHAVIORAL).

Who is sponsoring clinical trial NCT06360822?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06360822 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.